Slide 1: Nutriband Inc – NASDAQ: NTRB
Nutriband Inc 2023 All Rights Reserved NASDAQ: NTRB
Slide 2: About Nutriband
ABOUT NUTRIBAND Nutriband Inc (Nasdaq : NTRB) is a pharmaceutical company with a specific focus on transdermal technologies. Our model is to apply Transermal Tech to existing FDA approved drugs with a goal to improve safety, efficacy, patient comfort and more. Our first product and lead platform tec
Slide 3: About Nutriband
ABOUT NUTRIBAND We have structured our company to not follow the typical Biotech set up. At Nutriband, we have 2 revenue generating subsidiaries, 4P Therapeutics and Pocono Pharmaceutical along with Active Intelligence which specializes in sports recovery products We are earning revenues to keep our
Slide 4: Our Team
OUR TEAM Gareth Sheridan Serguei Melnik Dr. Alan Smith Dr. Jeff Patrick Founder and CEO Founder and President President 4P Therapeutics CSO Nutriband Nutriband Nutriband FDA Expert Committee on Complex Generics Gerald Goodman Paddy Ryan Michael Myer Tyler Overk Dianna Mather CFO Nutriband CTO Nutrib
Slide 5: Our Structure
OUR STRUCTURE 4P Therapeutics Pocono Pharmaceutical Active Intelligence Clinical and Regulatory Contract Manufacturing Product Subsidiary - Kinesiology Subsidiary Subsidiary Tapes 4P leads the execution of the Contract manufacturer for wide Focused on creating sports clinical/regulatory program rang
Slide 6: AVERSA abuse deterrent fentanyl transdermal system
AVERSA Our lead product is the AVERSA™ abuse deterrent fentanyl transdermal system
Slide 7: AVERSA abuse deterrent fentanyl transdermal system
AVERSA Our lead product is the AVERSA™ abuse deterrent fentanyl transdermal system AVERSA™ incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential Upon approval of AVERSA™ fentanyl, we expect that FDA will consider requiring all fent
Slide 8: National Drug-Involved Overdose Deaths
AVERSA Figure 1. National Drug-Involved Overdose Deaths* Number Among All Ages, by Gender, 1999-2020 100,000 mm Total 91,799 —— Female —— Male 80,000 60,000 40,000 20,000 0 DOS do 9H © KV oD OD WS AD 0 0h 0 1 AN 0S WD DO SPY SY AP OP 6 0 oN WD 0D of PFS GPF PG FF Po" PF A oP 9G *Includes deaths with
Slide 9: US Opioid Overdose Deaths
AVERSA US Opioid Overdose Deaths 1S 7 2015-2020 CAGR -—All Opioids* 16% 60 + other Synthetic Opioids (Primarily Fentanyl) 43% ——Heroin 0% 45 + — Commonly Prescribed Opioids -4% 30 4 Overdose Deaths (000s) 15 0+ + + + + + + + + + 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 * Opioid categor
Slide 10: AVERSA Fentanyl
AVERSA FENTANYL AVERSA™ Technology significantly reduces the likelihood of accidental exposure to fentanyl for children and pets. 32 cases of accidental fentanyl exposure have occurred since 1997, resulting in 12 deaths and 12 hospitalizations, mostly involving young children.
Slide 11: Fentanyl patch abuse routes
AVERSA AVERSA™ Fentanyl's goal is to provide a much less easily abused patch for the treatment of chronic pain 70+% of Fentanyl Patch Abusers Choose Oral Routes of Abuse Taste aversion addresses primary routes of abuse
Slide 12: Image of the Month: Colonoscopy Enables Diagnosis of Opiate Abuse
AVERSA IMAGE OF THE MONTH Colonoscopy Enables the Diagnosis of Opiate Abuse ® ‘Andrew P. Copland,” Jonathan P. Gaspar,* and Andrew Y. Wang’ “Dusen of Gastrerterangy and Hepatoingy Unenity of Yona Charotesrte Vepna "Gastoerteriogy Assooates of Fares Vegne . (OA-yeat old man with a history of chrveic
Slide 13: Abuse Deterrent Technology
AVERSA - ABUSE DETERRENT TECHNOLOGY A SOLUTION - Make it EXTREMELY unpleasant when misused
Slide 14: How does the AVERSA technology work?
AVERSA How does the AVERSA technology work?
Slide 15: Regulation on Opioids
AVERSA Regulation on Opioids: Aversa Fentanyl is well aligned with the mission of the Opioids Action Plan. AVERSA Fentanyl is aligned with the Plan’s mission to expand access to ADFs and to consider the risks of misuse not just by the patient, but also “by other persons who obtain [opioids]” Conserv
Slide 16: Regulatory
AVERSA Regulatory We have received positive Pre-IND feedback from the FDA for AVERSA Fentanyl AVERSA Fentanyl is a 505(b)(2) registration pathway AVERSA Fentanyl will be eligible for a 6- month expedited review based on precedent. Abuse Deterrence IP
Slide 17: AVERSA Fentanyl Market Opportunity
AVERSA AVERSA Fentanyl Market Opportunity
Slide 18: Kindeva Partnership
KINDEVA PARTNERSHIP Nutriband and Kindeva have built a strong partnership for AVERSA Fentanyl's commercial development, leading to significant progress in the abuse-deterrent patch's development and manufacturing. Signed feasibility agreement for AVERSA AVERSA Fentanyl estimated to reach peak Fentan
Slide 19: AVERSA market and go-to-market analysis
AVERSA Independent analysis conducted by an industry Buprenorphine continues to grow as treatment for leader for go to market strategy OUD (Opioid Use Disorder) AVERSA Fentanyl estimated to reach $80- 200MM peak annual sales on approval AVERSA Fentanyl, with initial study support, could gain wide ma
Slide 20: Large, Global Addressable Markets for AVERSA Platform Technology
AVERSA Large, Global Addressable Markets for AVERSA ™ Platform Technology
Slide 21: AVERSA forecasted peak annual sales
AVERSA According to Health Advances’ assessment and upon approval by the United States FDA, Aversa Fentanyl will be priced competitively with generic fentanyl patches and is expected to reach peak annual sales of $200 million. If non-ADF transdermal fentanyl products lose marketing approval, Aversa
Slide 22: AVERSA possible market with mandated abuse deterrence
AVERSA According to Health Advances’ assessment and upon approval by the United States FDA, Aversa Fentanyl will be priced competitively with generic fentanyl patches and is expected to reach peak annual sales of $200 million. If non-ADF transdermal fentanyl products lose marketing approval, Aversa
Slide 23: Pipeline
AVERSA PIPELILNE Pre-Clinical Phase I FDA Filing AVERSA™ Fentanyl Abuse Deterrent Indication AVERSA™ Transdermal Technology Chronic Pain Pre-Clinical Phase I FDA Filing AVERSA™ Buprenorphine Abuse Indication Chronic Pain Deterrent AVERSA™ Transdermal Technology Pre-Clinical Phase I FDA Filing AVERSA
Slide 24: 2022 results and milestones
Our 2022 results and milestones have shown that we remain laser focused on hitting the targets we set ourselves as a company each year. We have made significant progress with AVERSA and our goal to improve the safety profile of easily abused transdermal drugs. Our record financial results and multip
Slide 25: Want to know more?
WANT TO KNOW MORE? To find out more, or to enquire about our partnership options, please contact our team who can help find the right solution for your business. info@nutriband.com https://nutriband.com/ 121 S. Orange Ave., Suite 1500, Orlando, FL 32801 NASDAQ: NTRB